May 31, 2016

No Image

Today in Movie Culture: R-Rated 'X-Men: Apocalypse,' Steven Spielberg's Harvard Commencement Speech and More

Here are a bunch of little bites to satisfy your hunger for movie culture:

Redone Trailer of the Day:

Given Deadpool‘s success, Wired reimagined an R-rated version of X-Men: Apocalypse and made this Red Band trailer (via Geek Tyrant):

[embedded content]

Fan Build of the Day:

Speaking of X-Men: Apocalypse, learn how to make your own version of Psylocke’s psionic sword from the Hacksmith (via Design Taxi):

[embedded content]

Vintage Image of the Day:

Clint Eastwood, who turns 86 today, in his first film role as a laboratory assistant in Revenge of the Creature in 1954:

Meme of the Day:

The twitter feed @oscardances is swapping the music from the dance scene in Ex Machina to make Oscar Isaac and Sonoya Mizuno shake it to all kinds of other tunes, including the appropriate theme to Ghostbusters seen below (via Indiewire).

ghostbusters – ray parker jr. pic.twitter.com/iDNHWfzMEQ

— oscar dances (@oscardances) May 28, 2016

Fan Art of the Day:

This comic showing a parallel between events in Return of the Jedi and Star Wars: The Force Awakens will make you think of both scenes differently (via Geek Tyrant):

Commencement Speech of the Day:

Watch Steven Spielberg’s commencement to the Harvard class of 2016:

[embedded content]

Supercut of the Day:

Along with compiling the canonical list of greatest films by black directors, Slate made an accompanying supercut:

Fake Poster of the Day:

Some fans want Idris Elba to be the new James Bond, others want Tom Hiddleston, and this fake movie offers a compromise (via Red Scharlach):

Movie Celebration of the Day:

A fan of The World’s End cut a split-screen video to show all the foreshadowing lined up with what it foreshadows (via Edgar Wright):

[embedded content]

Classic Trailer of the Day:

Today is the 20th anniversary of Dragonheart. Watch the original trailer, starring a CG dragon with the voice of Sean Connery, below.

[embedded content]

Let’s block ads! (Why?)


No Image

As Olympics Near, Violence Grips Rio's 'Pacified' Favelas

A man performs yoga in the Babilonia favela overlooking Rio de Janeiro in 2014. The Brazilian government made a big push to impose order on the shantytowns in advance of the World Cup in 2014 and the Olympics this summer. Babilonia was once considered a model, but violence has been on the rise in the run-up to the games.

A man performs yoga in the Babilonia favela overlooking Rio de Janeiro in 2014. The Brazilian government made a big push to impose order on the shantytowns in advance of the World Cup in 2014 and the Olympics this summer. Babilonia was once considered a model, but violence has been on the rise in the run-up to the games. Mario Tama/Getty Images hide caption

toggle caption Mario Tama/Getty Images

In the misty rain, surrounded by Rio de Janeiro’s green hills, police officer Eduardo Dias was buried last week. He was shot, purportedly by gang members, as he was leaving his post inside the favela, or shantytown, where he worked as a community cop.

The killing took place a few hundred feet from the Maracana Stadium, where the opening ceremony of the Summer Olympics will be held on Aug. 5. As family members wept by the graveside, the pastor raised his hands.

“This rain is like our tears,” he said. “Not just ours, but coming also from the heavens for everything that we are going through. I have been asking God, until when, my Lord? Until when are we going to have to bury our good policemen? Until when will we have to keep burying our children?”

Brazil has been rattled by a terrible recession, multiple corruption scandals, a political meltdown and the Zika virus. And now Rio is suffering a security crisis.

Murders are up 15 percent from last year. Robbery is up 30 percent. Amid the economic and political turmoil, the state security budget has been cut by a third. The gangs are fighting for territory in advance of the Olympics, according to authorities.

While everyone is feeling the effects, the impact is greatest on Rio’s poorest communities, the favelas.

‘Disneyland’ Favela

To get a sense of how far things have slipped, I went back to Babilonia, a community I visited when I first arrived to Rio three years ago.

Babilonia, like many of Rio’s favelas, is located on a hillside with an amazing view of the water and the famed Copacabana beach. Babilonia became known as one of the so-called Disneyland favelas because they were shown to visiting dignitaries and the media as an example of how conditions had improved.

In the new and improved Babilonia, police walked around with their guns holstered. Residents were opening up businesses catering to tourists. They included restaurants, and hostels that were advertised on Airbnb. The drug gangs kept a low profile.

All this was part of a bold policing program called pacification, which placed permanent bases of community police, known as UPPs, in neighborhoods that had little or no state presence previously. Residents considered them long overdue and the state considered them necessary as Brazil prepared to host the World Cup in 2014 and this summer’s Olympics.

But unlike three years ago, the pacification police are now patrolling with their guns drawn. Police commander Paulo Berbat walks to the crest of the hill, where muddy paths disappear into the jungle.

He says six weeks ago, a rival gang from the neighboring favela tried to push in and take control from the group that controls the drugs and guns in Babilonia. Three drug dealers were killed in a firefight that sent fear through the community.

Too Scared To Speak

Rodrigo da Silva agreed to meet with me on the beach where he works. He owns a hostel in the favela that he advertises on Airbnb, but he also sells food on Copacabana to make ends meet.

He hoped the Summer Olympics would get him out of the hot sun. But so far, there have been few guests at his hostel. “Our business has decreased,” he says. “We had much higher expectations in terms of hosting people throughout the Olympics. If the situation had improved, maybe I wouldn’t still have to work here on the beach.”

Other members of the community had similar stories about a sharp drop in business due to the violence.

Aside from da Silva, favela residents refused to be interviewed, in marked contrast to three years ago. Several told me they had been directly threatened by the gangs, who said we were asking too many questions.

“If you talk too much, it ends badly,” da Silva says. “Here’s the deal: You do not mess with their business, don’t mess with their stuff — and they don’t mess with you.”

Olympic officials are promising the games will be safe for visitors and athletes. Brazil will be bringing in double the amount of security that the London Games had four years ago.

“What we need to push, and we will do so, is to have more security before the games, and more security after the games. We don’t want the games to be an island of success and perfection. We want the games to transform Rio, and to make Rio a safer city in the years to come,” says Mario Andrada, the communications director for Rio 2016.

But even if the Olympics go according to plan, the future of the pacification program is in doubt. Da Silva tells me he fears the worst.

“There will be more violence, more violence in all the communities because of the fights between the drug gangs, fights against the police,” he says. “In the end the ones who will pay for this will be the residents, as always.”

NPR has been collaborating with the the PBS NewsHour, which will also feature reporting by Lulu Garcia-Navarro on its program Tuesday evening.

Let’s block ads! (Why?)


No Image

Doctor Outlines Plan To Battle Antibiotic Resistance In 'The Washington Post'

NPR’s Ari Shapiro talks with Ezekiel Emanuel, a senior fellow at the Center for American Progress and chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania, about his opinion piece in the Washington Post that argues the cheap price of antibiotics has led to their overuse and has also discouraged drug companies from developing new antibiotics.

Transcript

ARI SHAPIRO: Unless we shift course, superbugs will become a fact of life. That line come from Zeke Emanuel, chair of the Department of Medical Ethics And Health Policy at the University of Pennsylvania. In The Washington Post, he lays out a four-pronged approach to avoid what he calls this nightmare scenario. Part of his argument is that antibiotics right now are too cheap, and he joins us to discuss the problem. Welcome to the program.

ZEKE EMANUEL: Nice to be here with you.

SHAPIRO: So there was news last week that a woman in Pennsylvania had a bacteria that was resistant to what’s known as an antibiotic of last resort, and that’s hit off this latest wave of concern about superbugs. Explain why you believe the price of antibiotics is partly to blame.

EMANUEL: Well, you know, the course of new, quote, unquote, “expensive antibiotics” might be $4,500 or $5,000. But a course of course of chemotherapy drug for cancer or a drug to fight multiple sclerosis can be $75,000, $100,000, $150,000 for a year of treatment.

And if you’re a drug company thinking about, where do I invest in terms of research and development – do I develop a $5,000, or do I developed $150,000 drug – you’re almost naturally going to go to the $150,000 drug. And so I think that’s a, you know – a major, major reason that we only have 37 antibiotics now in clinical development.

SHAPIRO: Could raising the prices of antibiotics have negative consequences as well?

EMANUEL: Well, of course. It’s going to happen (laughter). Everything has a positive and negative consequence. The negative consequence is it’s more expensive to treat these infections. Some people might not get them because the drugs are too expensive, although that’s pretty unlikely in the United States.

But I think in general, we have to shift the incentive structure for researchers and drug companies. Otherwise we’re just not going to have enough development.

SHAPIRO: Now, you’ve proposed that governments offer a $2 billion prize to drug companies for developing new antibiotics. Is this something that had been tried with other drugs before? Are prizes an effective motivator?

EMANUEL: I don’t know that they’ve been tried with any other drugs before. But we know in the past that prizes have worked. Napoleon offered a prize for someone who could preserve food for his army, and he got a guy who figured out how to sterilize food in a bottle and then a tin can. There was a prize by the British government to figure out naval navigation to go across the ocean. And Netflix offered a prize – actually, a very modest prize (laughter) – for figuring out people’s movie preferences.

So prizes have worked and have stimulated a lot of people to think about solutions. And from the perspective of the health system just in America – forget the rest of the world – we spend $20 billion on treating people with antibiotic-resistant infections.

So this is a small fraction of that, and it’s absolutely vital because if we have bacteria that we can’t treat, there are going to be a lot of people dying for lack of antibiotics. And that is not a scenario we can put up with.

SHAPIRO: So as you say, the numbers of antibiotics being developed are far lower than the numbers of, for example, cancer drugs being developed. And you also say that doctors over prescribe these drugs. Explain what’s going on.

EMANUEL: Yeah. We know from reports of antibiotic prescribing practices in hospitals that 20 to 50 percent of the antibiotics that are prescribed are either inappropriate for the actual organism or absolutely unnecessary to treat it.

And we know that produces side effects like C. difficile and other infection and that in the outpatient setting, in the physician’s office, about a third of the antibiotics are inappropriate or unnecessary because they’re treating viral infections, or they’re treating self-limited infections. That breeds a lot of resistance in the bacteria in the community, and that is a huge problem.

SHAPIRO: One thing you don’t mention in this piece is the role of patients. Is there something that patients should be doing differently in this problem?

EMANUEL: So there are two main things patients should be doing differently. One – don’t demand antibiotics for sore throats, runny noses, ear infections and put your doctor in the unfortunate circumstance of satisfying your demand and violating what he or she thinks is an appropriate care.

And the second is, when you do get a prescription for antibiotics, we know that a lot of patients do not complete the course of antibiotics. Instead of taking the full 10 days of an antibiotic, you take three or four. You’re feeling better. You stop. Well, then you’ve just bred some resistant organisms that are then going to proliferate, and the antibiotics that we have will not be as effective. And that is also a very big problem out there.

SHAPIRO: Doctor Zeke Emanuel is chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania, and he’s also a senior fellow at the Center for American Progress. Thanks for joining us.

EMANUEL: Thank you for having me and talking about superbugs and antibiotics.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)


No Image

Doctor Outlines Plan To Battle Antibiotic Resistance In 'The Washington Post'

NPR’s Ari Shapiro talks with Ezekiel Emanuel, a senior fellow at the Center for American Progress and chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania, about his opinion piece in the Washington Post that argues the cheap price of antibiotics has led to their overuse and has also discouraged drug companies from developing new antibiotics.

Transcript

ARI SHAPIRO: Unless we shift course, superbugs will become a fact of life. That line come from Zeke Emanuel, chair of the Department of Medical Ethics And Health Policy at the University of Pennsylvania. In The Washington Post, he lays out a four-pronged approach to avoid what he calls this nightmare scenario. Part of his argument is that antibiotics right now are too cheap, and he joins us to discuss the problem. Welcome to the program.

ZEKE EMANUEL: Nice to be here with you.

SHAPIRO: So there was news last week that a woman in Pennsylvania had a bacteria that was resistant to what’s known as an antibiotic of last resort, and that’s hit off this latest wave of concern about superbugs. Explain why you believe the price of antibiotics is partly to blame.

EMANUEL: Well, you know, the course of new, quote, unquote, “expensive antibiotics” might be $4,500 or $5,000. But a course of course of chemotherapy drug for cancer or a drug to fight multiple sclerosis can be $75,000, $100,000, $150,000 for a year of treatment.

And if you’re a drug company thinking about, where do I invest in terms of research and development – do I develop a $5,000, or do I developed $150,000 drug – you’re almost naturally going to go to the $150,000 drug. And so I think that’s a, you know – a major, major reason that we only have 37 antibiotics now in clinical development.

SHAPIRO: Could raising the prices of antibiotics have negative consequences as well?

EMANUEL: Well, of course. It’s going to happen (laughter). Everything has a positive and negative consequence. The negative consequence is it’s more expensive to treat these infections. Some people might not get them because the drugs are too expensive, although that’s pretty unlikely in the United States.

But I think in general, we have to shift the incentive structure for researchers and drug companies. Otherwise we’re just not going to have enough development.

SHAPIRO: Now, you’ve proposed that governments offer a $2 billion prize to drug companies for developing new antibiotics. Is this something that had been tried with other drugs before? Are prizes an effective motivator?

EMANUEL: I don’t know that they’ve been tried with any other drugs before. But we know in the past that prizes have worked. Napoleon offered a prize for someone who could preserve food for his army, and he got a guy who figured out how to sterilize food in a bottle and then a tin can. There was a prize by the British government to figure out naval navigation to go across the ocean. And Netflix offered a prize – actually, a very modest prize (laughter) – for figuring out people’s movie preferences.

So prizes have worked and have stimulated a lot of people to think about solutions. And from the perspective of the health system just in America – forget the rest of the world – we spend $20 billion on treating people with antibiotic-resistant infections.

So this is a small fraction of that, and it’s absolutely vital because if we have bacteria that we can’t treat, there are going to be a lot of people dying for lack of antibiotics. And that is not a scenario we can put up with.

SHAPIRO: So as you say, the numbers of antibiotics being developed are far lower than the numbers of, for example, cancer drugs being developed. And you also say that doctors over prescribe these drugs. Explain what’s going on.

EMANUEL: Yeah. We know from reports of antibiotic prescribing practices in hospitals that 20 to 50 percent of the antibiotics that are prescribed are either inappropriate for the actual organism or absolutely unnecessary to treat it.

And we know that produces side effects like C. difficile and other infection and that in the outpatient setting, in the physician’s office, about a third of the antibiotics are inappropriate or unnecessary because they’re treating viral infections, or they’re treating self-limited infections. That breeds a lot of resistance in the bacteria in the community, and that is a huge problem.

SHAPIRO: One thing you don’t mention in this piece is the role of patients. Is there something that patients should be doing differently in this problem?

EMANUEL: So there are two main things patients should be doing differently. One – don’t demand antibiotics for sore throats, runny noses, ear infections and put your doctor in the unfortunate circumstance of satisfying your demand and violating what he or she thinks is an appropriate care.

And the second is, when you do get a prescription for antibiotics, we know that a lot of patients do not complete the course of antibiotics. Instead of taking the full 10 days of an antibiotic, you take three or four. You’re feeling better. You stop. Well, then you’ve just bred some resistant organisms that are then going to proliferate, and the antibiotics that we have will not be as effective. And that is also a very big problem out there.

SHAPIRO: Doctor Zeke Emanuel is chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania, and he’s also a senior fellow at the Center for American Progress. Thanks for joining us.

EMANUEL: Thank you for having me and talking about superbugs and antibiotics.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)